Antibody Binding to Tie2 and Use Thereof

1 .- 13 . (canceled)

14 . A nucleic acid encoding an anti-Tie2 antibody or antigen-binding fragment thereof which binds Tie2 Ig3-FNIII (1-3) domain comprising the sequence of SEQ ID NO:2, wherein the antibody or antigen-binding fragment thereof comprises:

a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs: 3-5, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs: 6-8, respectively;

a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs: 13-15, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs: 16-18, respectively;

a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs: 23-25, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs: 26-28, respectively;

a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs: 33-35, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs: 36-38, respectively; or

a heavy chain variable region comprising heavy chain CDRH1, CDRH2, and CDRH3 comprising amino acid sequences of SEQ ID NOs: 43-45, respectively, and a light chain variable region comprising light chain CDRL1, CDRL2, and CDRL3 comprising amino acid sequences of SEQ ID NOs: 46-48, respectively.

15 . The nucleic acid of claim 14 , wherein the antibody or antigen-binding fragment thereof comprises:

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 9 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 11;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 19 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 21;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 29 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 31;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 39 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 41;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 49 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 51;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 53 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 54;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 57 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 58;

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 61 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 62; or

a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 65 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 66.

16 . The nucleic acid of claim 14 , wherein the nucleic acid comprises:

nucleotide sequences of SEQ ID NOs: 10 and 12;

nucleotide sequences of SEQ ID NOs: 20 and 22;

nucleotide sequences of SEQ ID NOs: 30 and 32;

nucleotide sequences of SEQ ID NOs: 40 and 42;

nucleotide sequences of SEQ ID NOs: 50 and 52;

nucleotide sequences of SEQ ID NOs: 55 and 56;

nucleotide sequences of SEQ ID NOs: 59 and 60;

nucleotide sequences of SEQ ID NOs: 63 and 64; or nucleotide sequences of SEQ ID NOs: 67 and 68.

17 . The nucleic acid of claim 14 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising heavy chain CDRs comprising amino acid sequences of SEQ ID NOs: 23-25 and a light chain variable region comprising light chain CDRs comprising amino acid sequences of SEQ ID NOs: 26-28.

18 . The nucleic acid of claim 15 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising amino acid sequence of SEQ ID NO: 29 and a light chain variable region comprising amino acid sequence of SEQ ID NO: 31.

19 . The nucleic acid of claim 16 , wherein the nucleic acid comprises nucleotide sequences of SEQ ID NOs: 30 and 32.

20 . An expression vector comprising the nucleic acid of claim 14 .

21 . An expression vector comprising the nucleic acid of claim 17 .

22 . An expression vector comprising the nucleic acid of claim 18 .

23 . A cell transformed with the expression vector of claim 20 .

24 . A cell transformed with the expression vector of claim 21 .

25 . A cell transformed with the expression vector of claim 22 .

26 . A method of manufacturing an antibody or antigen-binding fragment thereof which binds Tie2, comprising the steps of:

(a) culturing the cell of claim 23 ; and

(b) recovering an antibody or antigen-binding fragment thereof from the cultured cell.

27 . A method of manufacturing an antibody or antigen-binding fragment thereof which binds Tie2, comprising the steps of:

(a) culturing the cell of claim 24 ; and

(b) recovering an antibody or antigen-binding fragment thereof from the cultured cell.

28 . A method of manufacturing an antibody or antigen-binding fragment thereof which binds Tie2, comprising the steps of:

(a) culturing the cell of claim 25 ; and

(b) recovering an antibody or antigen-binding fragment thereof from the cultured cell.